Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | +2.48% | -23.93% | +16.98% |
Sales 2024 * | - | Sales 2025 * | 50.61M 69.71M | Capitalization | 69.77M 96.11M |
---|---|---|---|---|---|
Net income 2024 * | -40M -55.1M | Net income 2025 * | -50M -68.87M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.38 x |
P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-1.08
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Latest transcript on SELLAS Life Sciences Group, Inc.
1 day | +2.48% | ||
1 week | -23.93% | ||
1 month | +22.77% | ||
3 months | +93.75% | ||
6 months | +27.82% | ||
Current year | +16.98% |
Managers | Title | Age | Since |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 06-04-02 |
John Burns
DFI | Director of Finance/CFO | 39 | 13-04-30 |
Andrew Elnatan
LAW | General Counsel | - | 23-01-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 17-12-28 | |
David Scheinberg
BRD | Director/Board Member | 68 | 17-11-30 |
John Varian
BRD | Director/Board Member | 64 | 17-12-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 1.24 | +2.48% | 1,104,224 |
24-04-29 | 1.21 | -17.12% | 3,332,762 |
24-04-26 | 1.46 | -3.95% | 1,292,455 |
24-04-25 | 1.52 | -1.30% | 657,949 |
24-04-24 | 1.54 | -5.52% | 1,318,570 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.98% | 69.77M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.42% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- SLS Stock